Review Article
Mesenchymal Stem Cell-derived Exosomes: Novel Therapeutic Approach for Inflammatory Bowel Diseases
Table 1
Therapeutic application of MSC-Exo in IBD treatment.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
AD-MSCS: adipose mesenchymal stem cells; DSS: dextran sulfate sodium; Exo: exosomes; hBM-MSCs: human bone marrow mesenchymal stem cells; HMGB3: high-mobility group box 3 protein; HOXB13: high-mobility group box 13 protein; hUC-MSCs: human umbilical cord mesenchymal stem cells; IBD: inflammatory bowel diseases; IECs: induced embryonic stem cells; IL-18: interleukin-18; IL-1β: interleukin-1β; IL-7: interleukin-7; iNOS: inducible nitric oxide synthase; MT-2: metallothi-onein-2; N/A: not Available; NF-κB: nuclear factor kappa-B; NLRP3: NOD-like receptor thermal protein domain associated protein 3; Olfactory Ecto-MSCs: olfactory ecto mesenchymal stem cells; Stat3: signal transducer and activator of transcription 3; SUMO1: small ubiquitin-like modifier 1; TGF-β: transforming growth factor-β; Th17: T helper 17 cells; Th2: T helper 2 cells; TJ: tight junctions; TSG-6: tumor necrosis factor-α stimulated gene 6; VEGF: vascular endothelial growth factor. |